Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies

IF 4.3 3区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutical Sciences Pub Date : 2024-10-17 DOI:10.1016/j.ejps.2024.106939

Elsayed A. Elmorsy , Sameh Saber , Rabab S. Hamad , Mustafa Ahmed Abdel-Reheim , Attalla F. El-kott , Mohammed A. AlShehri , Kareem Morsy , Salama A. Salama , Mahmoud E. Youssef

{"title":"Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies","authors":"Elsayed A. Elmorsy , Sameh Saber , Rabab S. Hamad , Mustafa Ahmed Abdel-Reheim , Attalla F. El-kott , Mohammed A. AlShehri , Kareem Morsy , Salama A. Salama , Mahmoud E. Youssef","doi":"10.1016/j.ejps.2024.106939","DOIUrl":null,"url":null,"abstract":"<div><div>Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review aims to provide a comprehensive overview of cisplatin toxicity, encompassing its underlying mechanisms, risk factors, and emerging therapeutic strategies. The mechanisms of cisplatin toxicity are multifactorial and involve oxidative stress, inflammation, DNA damage, and cellular apoptosis. Various risk factors contribute to the interindividual variability in susceptibility to cisplatin toxicity. The risk of developing cisplatin-induced toxicity could be related to pre-existing conditions, including kidney disease, hearing impairment, neuropathy, impaired liver function, and other comorbidities. Additionally, this review highlights the emerging therapeutic strategies that could be applied to minimize cisplatin-induced toxicities and aid in optimizing cisplatin treatment regimens, improving patient outcomes, and enhancing the overall quality of cancer care.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"203 ","pages":"Article 106939"},"PeriodicalIF":4.3000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098724002525","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Cisplatin, a widely used chemotherapeutic agent, has proven efficacy against various malignancies. However, its clinical utility is hampered by its dose-limiting toxicities, including nephrotoxicity, ototoxicity, neurotoxicity, and myelosuppression. This review aims to provide a comprehensive overview of cisplatin toxicity, encompassing its underlying mechanisms, risk factors, and emerging therapeutic strategies. The mechanisms of cisplatin toxicity are multifactorial and involve oxidative stress, inflammation, DNA damage, and cellular apoptosis. Various risk factors contribute to the interindividual variability in susceptibility to cisplatin toxicity. The risk of developing cisplatin-induced toxicity could be related to pre-existing conditions, including kidney disease, hearing impairment, neuropathy, impaired liver function, and other comorbidities. Additionally, this review highlights the emerging therapeutic strategies that could be applied to minimize cisplatin-induced toxicities and aid in optimizing cisplatin treatment regimens, improving patient outcomes, and enhancing the overall quality of cancer care.

Abstract Image

查看原文本刊更多论文

理解顺铂诱导毒性的进展：分子机制与保护策略》。

顺铂是一种广泛使用的化疗药物，对各种恶性肿瘤的疗效已得到证实。然而，其剂量限制性毒性（包括肾毒性、耳毒性、神经毒性和骨髓抑制）阻碍了其临床应用。本综述旨在全面概述顺铂毒性，包括其潜在机制、风险因素和新兴治疗策略。顺铂毒性的机制是多因素的，涉及氧化应激、炎症、DNA 损伤和细胞凋亡。各种风险因素导致了顺铂毒性易感性的个体差异。发生顺铂诱导毒性的风险可能与原有疾病有关，包括肾脏疾病、听力损伤、神经病变、肝功能受损和其他合并症。此外，本综述还重点介绍了可用于尽量减少顺铂诱导毒性的新兴治疗策略，这些策略有助于优化顺铂治疗方案、改善患者预后和提高癌症护理的整体质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pharmaceutical Sciences 医学-药学

CiteScore

9.60

自引率

2.20%

发文量

248

审稿时长

50 days

期刊介绍： The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.